Synthesis and Anti-Cancer Activity In Vitro of Synephrine Derivatives.
Ontology highlight
ABSTRACT: Glucocorticoids (GCs) are routinely used to treat hematological malignancies; however, long-term treatment with GCs can lead to atrophic and metabolic adverse effects. Selective glucocorticoid receptor agonists (SEGRAs) with reduced side effects may act as a superior alternative to GCs. More than 30 SEGRAs have been described so far, yet none of them reached clinical trials for anti-cancer treatment. In the present work, we propose a novel approach to increase the number of potential SEGRAs by obtaining derivatives of synephrine, a molecule of natural origin. We synthesized 26 novel compounds from the class of synephrine derivatives and characterized them by HRMS, and 1H and 13C NMR. We evaluated in vitro anti-cancer effects in leukemia K562 and lymphoma Granta
SUBMITTER: Zhidkova EM
PROVIDER: S-EPMC11762542 | biostudies-literature | 2024 Dec
REPOSITORIES: biostudies-literature
ACCESS DATA